Indirubin-3′-monoxime (CAS 160807-49-8)

Indirubin-3′-monoxime, a chemical compound derived from the naturally occurring indirubin, has become a valuable tool in scientific research, particularly in the field of cell biology and signal transduction. Its mechanism of action involves inhibiting cyclin-dependent kinases (CDKs), specifically CDK1 and CDK5, by competing with ATP binding at the catalytic site. This inhibition results in cell cycle arrest and modulation of various cellular processes regulated by CDK activity, such as proliferation, differentiation, and apoptosis. Additionally, indirubin-3′-monoxime has been shown to exhibit anti-inflammatory properties by suppressing the activity of glycogen synthase kinase-3β (GSK-3β) and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. In research settings, indirubin-3′-monoxime has been extensively used to investigate the functions of CDKs and their involvement in cellular processes, including neurogenesis, neuronal differentiation, and synaptic plasticity. Moreover, its ability to modulate CDK activity has led to its exploration as an agent in neurological disorders, such as Alzheimer′s disease and Parkinson′s disease, as well as in cancer research. Overall, indirubin-3′-monoxime serves as a versatile tool for unraveling the complexities of cell signaling pathways and holds promise for the development of novel interventions targeting CDKs and associated pathways in various pathological conditions.